MedTrace Logo

A Phase I Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell)

NCT07633197 · Status: ENROLLING_BY_INVITATION · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-06-08

No results posted yet for this study

Summary

To evaluate the safety and tolerability of different dosages of recombinant zoster vaccine (CHO cell) when administered to adults aged 40 years and older.

Conditions

  • Herpes

Interventions

BIOLOGICAL

Recombinant Herpes Zoster Vaccine

This product is for intramuscular injection only, with the deltoid muscle of the upper arm as the preferred vaccination site. The immunization schedule consists of two doses at 0.5 ml per dose, and the second dose shall be administered two months apart from the first dose.

BIOLOGICAL

adjuvant placebo

This product is for intramuscular injection only, with the deltoid muscle of the upper arm as the preferred vaccination site. The immunization schedule consists of two doses at 0.5 ml per dose, and the second dose shall be administered two months apart from the first dose.

BIOLOGICAL

Placebo

This product is for intramuscular injection only, with the deltoid muscle of the upper arm as the preferred vaccination site. The immunization schedule consists of two doses at 0.5 ml per dose, and the second dose shall be administered two months apart from the first dose.

Sponsors & Collaborators

  • Changchun BCHT Biotechnology Co.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-05-28
Primary Completion
2026-12-28
Completion
2027-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07633197 on ClinicalTrials.gov